Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer

J Clin Pathol. 2007 Sep;60(9):1067-8. doi: 10.1136/jcp.2006.043356. Epub 2007 Feb 9.
No abstract available

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics
  • Carcinoma, Ductal, Breast / diagnosis*
  • Carcinoma, Ductal, Breast / drug therapy
  • Carcinoma, Ductal, Breast / genetics
  • Chromogenic Compounds
  • Female
  • Genes, erbB-2*
  • Humans
  • In Situ Hybridization / methods
  • Patient Selection
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Chromogenic Compounds
  • Trastuzumab